Weight-loss drugs are becoming a popular perk, with almost a third of workers saying they’d even switch jobs for it. Bank of America has them covered.

Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.

CEO Brian Moynihan says GLP-1 medications now account for roughly 13% of the bank's total annual healthcare spending